Table 4.
Disease-free survival analyses according to preoperative LMR in 680 patients with ESCC.
| Variables | Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| Sex (male vs. female) | 1.246 | 0.826-1.879 | 0.295 | ||||
| Age (>60 vs. ≤60) | 0.995 | 0.977-1.012 | 0.559 | ||||
| Depth of tumor (3 vs. 1+2) | 1.143 | 0.909-1.439 | 0.253 | ||||
| Lymph node metastasis (+ vs. -) | 1.667 | 1.453-1.910 | <0.001 | 1.648 | 1.314-2.068 | <0.001 | |
| Pathological stage (3 vs. 1+2) | 1.64 | 1.332-2.021 | <0.001 | 0.84 | 0.611-1.157 | 0.286 | |
| Vessel invasive (+ vs. -) | 1.382 | 1.037-1.842 | 0.027 | 0.81 | 0.578-1.136 | 0.222 | |
| Nerve infiltration (+ vs. -) | 1.643 | 1.250-2.159 | <0.001 | 1.57 | 1.160-2.126 | 0.003 | |
| Treatment regimen (S vs. S+CRT/C) |
1.306 | 1.170-1.458 | <0.001 | 1.299 | 1.147-1.471 | <0.001 | |
| Hospital time after operation(days) (>14 vs. ≤14) | 1.003 | 0.989-1.017 | 0.716 | ||||
| LMR (≥3.17 vs. <3.17) | 0.892 | 0.810-0.982 | 0.020 | 0.854 | 0.768-0.949 | 0.003 | |
Abbreviations: S: surgery; C: chemotherapy; CRT: chemoradiotherapy; LMR: lymphocyte to monocyte ratio.